NATCO Launches Generic Bosentan Tablets for Oral Suspension in the U.S. with 180-Day Exclusivity
Hyderabad, India, August 20, 2025 – NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) today announced the launch of...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Hyderabad, India, August 20, 2025 – NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) today announced the launch of...
SmartLabs and Sonrai Analytics today announced a global strategic alliance to integrate Sonrai’s next-generation AI platform, Sonrai Discovery, into...
Stramsen Biotech Inc., a plant-based biotechnology company, has announced the submission of its Pre-Investigational New Drug (Pre-IND) package to...
Shanghai – August 28, 2025 — D3 Bio, Inc., a clinical-stage precision oncology company, announced that the U.S. Food...
The FDA has approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax for the 2025-2026 season, targeting high-risk groups....
The FDA approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax while ending broad Emergency Use Authorization. Eligibility is...
RNAConnect today announced the commercial launch of the UltraMarathonRT® (uMRT) cDNA Synthesis and Amplification Kit, a next-generation tool designed...
SHIRLEY, N.Y., August 27, 2025 — American Regent, Inc.® has announced the commercial launch of Gvoke VialDx™ (glucagon injection),...
MONTREAL, Aug. 18, 2025 — Glycovax Pharma has secured a license from the National Research Council of Canada (NRC)...
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate bretisilocin (GM-2505), a next-generation...
